

1 **Rapid DNA methylation-based classification of pediatric brain tumours from**
2 **ultrasonic aspirate specimens**

3

4 Michèle Simon^{1*}, Luis P. Kuschel^{2*}, Katja von Hoff³, Dongsheng Yuan², Pablo
5 Hernáiz Driever¹, Elisabeth G. Hain⁴, Arend Koch⁴, David Capper^{4,5}, Matthias Schulz⁶,
6 Ulrich-Wilhelm Thomale^{6*}, Philipp Euskirchen^{2,4,5*}

7

8 1 Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin
9 and Humboldt Universität zu Berlin, Department of Pediatric Oncology and
10 Hematology, Berlin, Germany

11 2 Charité-Universitätsmedizin Berlin, Department of Neurology, Berlin, Germany

12 3 Department of Paediatric and Adolescent Medicine, Aarhus University Hospital,
13 Aarhus, Denmark

14 4 Charité-Universitätsmedizin Berlin, Department of Neuropathology, Berlin,
15 Germany

16 5 German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer
17 Research Center (DKFZ), Heidelberg, Germany

18 6 Charité-Universitätsmedizin Berlin, Department of Pediatric Neurosurgery, Berlin,
19 Germany

20 *authors contributed equally

21

22 Corresponding Author:

23 Philipp Euskirchen, MD

24 Department of Neuropathology

25 Charité – Universitätsmedizin Berlin

26 Charitéplatz 1

27 10117 Berlin

28 Germany

29 E-Mail: philipp.euskirchen@dkfz.de

30

31

32 Keywords:

33 nanopore sequencing, pediatric brain cancer, ultrasonic aspirator

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61

Abstract

Background: Although cavitating ultrasonic aspirators are commonly used in neurosurgical procedures, the suitability of ultrasonic aspirator-derived tumor material for diagnostic procedures is still controversial. Here, we explore the feasibility of using ultrasonic aspirator-resected tumor tissue to classify otherwise discarded sample material by fast DNA methylation-based analysis using low pass nanopore whole genome sequencing.

Methods: ultrasonic aspirator-derived specimens from pediatric patients undergoing brain tumour resection were subjected to low-pass nanopore whole genome sequencing. DNA methylation-based classification using a neural network classifier and copy number variation analysis were performed. Tumor purity was estimated from copy number profiles. Results were compared to microarray (EPIC)-based routine neuropathological histomorphological and molecular evaluation.

Results: 18 samples with confirmed neuropathological diagnosis were evaluated. All samples were successfully sequenced and passed quality control for further analysis. DNA and sequencing characteristics from ultrasonic aspirator-derived specimens were comparable to routinely processed tumor tissue. Classification of both methods was concordant regarding methylation class in 16/18 (89%) cases. Application of a platform-specific threshold for nanopore-based classification ensured a specificity of 100%, whereas sensitivity was 78%. Copy number variation profiles were generated for all cases and matched EPIC results in 16/18 (89%) samples, even allowing the identification of diagnostically or therapeutically relevant genomic alterations.

Conclusion: Methylation-based classification of pediatric CNS tumors based on ultrasonic aspirator-reduced and otherwise discarded tissue is feasible using time- and cost-efficient nanopore sequencing.

62

63 **Introduction**

64

65 Ultrasonic aspirator devices are frequently used in pediatric neurosurgery for efficient
66 microsurgical resection of brain tumours while minimizing tissue damage to
67 surrounding healthy brain (1). With ultrasonic aspirator, tumor tissue is fragmented in
68 situ by ultrasound-induced vibration and tissue debris is aspirated using suction. To
69 date, ultrasonic aspirator tissue specimens have not been used for routine
70 neuropathological examinations. At the same time, molecular profiling is increasingly
71 used and required in addition to histomorphology for diagnostic workup and
72 comprehensive characterization of pediatric brain tumours (2). In particular molecular
73 classification based on DNA methylation signatures has proven to be a powerful and
74 elegant unbiased approach to identifying tumor type (3) and has been adopted in the
75 current World Health Organization (WHO) classification of central nervous system
76 (CNS) tumours (4). For DNA extraction, however, additional tissue is needed which
77 may be scarce in pediatric neurosurgery. While for histological examination it
78 appears necessary to preserve the integrity of the tissue, DNA methylation profiling
79 (as any nucleic acid-based method) only relies on the integrity of tumor DNA.
80 Repurposing ultrasonic aspirator tissue specimens as a source of tumor DNA for
81 molecular diagnostics would maximize use of tumor tissue. To date, only detection of
82 focal amplifications (5) and gene expression profiling by RNA sequencing (6) in
83 ultrasonic aspirator tissue samples have been explored .

84 The growth patterns of pediatric brain tumors differ from those of adult tumors in that
85 they are more likely to spread in the neuraxis (7). Furthermore, highly aggressive
86 rare embryonal and sarcomatous pediatric CNS tumors for which there are limited
87 therapeutic recommendations and for which immediate initiation of therapy is
88 essential have only recently been molecularly redefined (8). The overall time to
89 integrated diagnosis in pediatric oncology is therefore of considerable importance,
90 and any delay in initiating first-line therapy may be critical. Indeed, the presence of
91 molecular markers defining risk groups in therapy trials also leads to different
92 therapeutic approaches.

93 Recently, we have demonstrated, that low-pass nanopore whole genome sequencing
94 (WGS) is non-inferior to microarray-based DNA methylation profiling of CNS tumors
95 (9). In addition, real-time analysis is feasible, enabling a reliable intraoperative

96 diagnosis within a surgically relevant time frame at low cost (10). In addition, adaptive
97 sequencing allows to enrich genomic regions of interest in the same WGS run to
98 detect clinically relevant SNV and SV (11).

99 In the present study, we studied whether DNA methylation-based classification can
100 be reliably performed using DNA from tumor tissue fragments obtained by ultrasonic
101 aspirator devices using low-pass nanopore whole genome sequencing in order to
102 overcome time-consuming tissue processing and maximize use of limited material in
103 pediatric neuro-oncology.

104 105 **Methods**

106 107 **Study design**

108 We conducted a prospective, proof-of-concept single-center study using ultrasonic
109 aspirator tissue specimens for molecular characterization of pediatric CNS tumors
110 using nanopore WGS (Fig. 1 (A)). All patients < 18 years who underwent surgery for
111 tumor resection using an ultrasonic aspiration device at the Department of Pediatric
112 Neurosurgery, Charité-Universitätsmedizin Berlin, Germany, between February 6th,
113 2020, and October 5th, 2020, were screened. Informed written consent was obtained
114 from patients and/or guardians. The study was approved by the local ethics
115 committee (Charité –Universitätsmedizin Berlin, Berlin, Germany; EA2/041/18) and
116 performed according to the guidelines for Good Scientific Practice. Ultrasonic
117 aspirator tissue samples taken with the LEVICS device (Söring, Quickborn,
118 Germany), which are normally discarded after surgery, are collected using a
119 bronchoalveolar lavage trap, which is connected to the suction tubing coming from
120 the sonotrode instruments and connected to the suction reservoir. Thereby about 5ml
121 of fluid including fragmented tumor tissue could be collected. In parallel, regularly
122 resected tumor tissue was processed for routine neuropathological procedures
123 including phenotypic-genotypic diagnostics. All study data were archived under an ID
124 key accessible only to the research group (pseudonymization). Pseudonymized study
125 data were recorded using REDCap (13), which was provided by the Berlin Institute of
126 Health's Clinical Research Unit in a certified computing environment.

127 128 **Ultrasonic aspirator tissue sample processing**

129 Fresh ultrasonic aspirator fluid aliquots were centrifuged at 1.000 rpm for 5
130 min, supernatant was discarded and pellets stored at -40°C. DNA was extracted from
131 ~25 mg thawed aspirate and purified using the DNeasy Blood & Tissue Kit (Qiagen,
132 NL). Based on the 260/280 ratio (NanoDrop, Thermo Fisher, USA), DNA quality was
133 determined, followed by DNA quantification with a Qubit 4.0 fluorometer using a
134 dsDNA BR Assay (Thermo Fisher, USA).

135

136 **Nanopore low-pass whole genome sequencing**

137 All samples were subjected to low-pass whole genome sequencing as described
138 previously (9). Preprocessing of raw data for sequencing was performed using the
139 publicly available nanoDx pipeline (<https://gitlab.com/pesk/nanoDx>, v0.5.1). Briefly,
140 basecalling of nanopore FAST5 raw data was performed using guppy v5.0.16
141 (Oxford Nanopore Technologies, UK) and aligned to the hg19 human reference
142 genome using minimap2 v2.15 (14). In order to assess the feasibility of ultrasonic
143 aspirator-derived nanopore sequencing, the aligned sequencing data was normalized
144 to a six hour sequencing window and were compared to a previously published
145 dataset of 16 brain tumor samples obtained during routine nanopore sequencing
146 from fresh-frozen tumor tissue (9). DNA methylation was assessed using nanopolish
147 v0.11.1 (15). After binarization of beta values with threshold = 0.6 (9), features with
148 zero variance were filtered out, leading to 366,263 CpG sites retained. These were
149 used to train the neural network model with randomly masked features. PyTorch, an
150 open source deep-learning framework, was used to develop the model (16). To
151 obtain class probability estimates that can be used to guide diagnostic decision-
152 making, a normalization function and a Softmax layer was used to convert the raw
153 values into a probability that measures the confidence in the brain tumor class
154 assignment (the calibrated score). Returned majority votes were combined to
155 methylation class families (MCF), if feasible (9). Complementarily, data was
156 displayed using t-distributed Stochastic Neighborhood Embedding (t-SNE) (17).

157

158 **CNS tumor classification**

159 All cases were classified according to the 2016 WHO CNS classification during
160 routine neuropathological examination at the Department of Neuropathology, Charité
161 Universitätsmedizin Berlin. The recent 2021 edition (4) was not yet available during
162 the study period of this patient cohort. Nanopore classification results were compared

163 to the reference diagnosis as well as microarray-based classification results of the
164 same tumor considering the established cut-off values for the probability score.

165

166 **Copy number analysis**

167 Copy number variation (CNV) analysis from nanopore WGS data was performed
168 using the QDNAseq package v1.8.0 and R/Bioconductor v3.3 as described before
169 (18, 19). To account for region- and technology-specific artifacts, public nanopore
170 WGS data for the NA12878 human reference genome were processed and
171 subtracted from the normalized bin counts of the tumor samples for case reports. To
172 estimate tumor purity in aneuploid tumors, absolute copy number estimation of
173 nanopore- and microarray-based data was performed using the ACE software
174 package (v1.6.0) (20). All estimates were verified manually.

175

176 **Methylation array processing**

177 Infinium MethylationEPIC BeadChip microarrays (Illumina) were used to obtain
178 genome-wide DNA methylation profiles for tumor samples during routine
179 neuropathological diagnostic examination. Data were generated following the
180 manufacturer's protocol at the Department of Neuropathology, Charité -
181 Universitätsmedizin Berlin, using >250 ng of DNA from FFPE tissues as input
182 material. For classification, IDAT files were uploaded to the public Heidelberg brain
183 tumour classifier available at <https://www.molecularneuropathology.org> (v.11b4).

184 **Statistical analysis**

185 Reproducible and easy-to-deploy pipelines were implemented using snakemake
186 (v.7.15.2) (21). Data analysis was mainly performed using R (v.4.0.2). Figures were
187 designed using ggplot2 (v.3.3.2). Statistical analyses were performed using IBM
188 SPSS® 29 (Armonk, N.Y., USA)

189

190 **Data and code availability**

191 The nanoDx analysis pipeline for end-to-end analysis of nanopore WGS data is
192 available at <https://gitlab.com/pesk/nanoDx> (v.0.5.1). Source code to reproduce all
193 analyses and sequencing data based figures in this work is provided at
194 <https://gitlab.com/pesk/nanoCUSA>. Raw sequencing data have been deposited at the
195 European Genome-phenome archive (accession no. tbd), while methylation

196 microarray data and nanopore methylation calls are available from Gene Omnibus
197 Express (accession no. tbd).

198 199 **Results**

200 201 **Patient characteristics**

202 A total of 21 children undergoing surgery participated in the study. 3/21 (14.9%) of
203 patients were excluded from analysis due to non-diagnostic scores in microarray-
204 based classification (n=2) or final diagnosis of non-neoplastic disease (n=1).
205 Eventually, our cohort comprised 18 tumor aspirates from 18 pediatric patients (Table
206 1). 33% of patients (n=6) were male. Median age at surgery was 7.5 years (range 1
207 to 17 years). Twelve patients suffered from a newly diagnosed cerebral lesion,
208 whereas six samples were obtained from a second or further intervention. Five
209 patients had received previous treatment with vincristine/carboplatin according to the
210 European guidelines for low-grade glioma (LGG) (n=4) or
211 cyclophosphamide/vincristine/methotrexate/carboplatin/etoposide according to the
212 current treatment recommendation of the German Society of Pediatric Oncology and
213 Hematology (GPOH) for newly diagnosed medulloblastoma, ependymoma, and
214 pineoblastoma (n=1). One patient with LGG was previously treated with vinblastine
215 monotherapy and targeted therapy using a MEK inhibitor. The most frequent
216 diagnosis was pilocytic astrocytoma (50%, n=9).

217 218 **Sequencing characteristics of tumor DNA from ultrasonic aspirator tissue** 219 **samples**

220 Low-pass whole genome sequencing performed for at least 6 hours resulted in a
221 mean genome coverage of 0.44X (range 0.01X to 1.5X, Suppl. Table 1). The mean
222 read length ranged between 4,047 and 10,440 base pairs with a mean of 7,377 base
223 pairs and was comparable to reads obtained in an external cohort of sequencing runs
224 of tumor DNA extracted from fresh-frozen tissue (Fig. 1B). The mean number of CpG
225 sites overlapping the reference atlas was 100,852 CpGs (range: 2,275 to 295,872
226 CpG sites), exceeding the minimum number of 1,000 overlapping CpG sites for
227 meaningful analysis in 18/18 (100%) samples. In two cases, the minimum number of
228 CpG sites was not achieved initially and required an additional sequencing run. On
229 average, after six hours of sequencing 1,054 Mb of aligned base pairs were obtained

230 (range: 23.76 Mb - 2299.12 Mb), which again was comparable to sequencing runs
231 from fresh-frozen tissue (Fig. 1C). Tumor cell content was reliably estimated from
232 copy number alterations in 4/20 (20%) tumors with a mean tumor purity of 0.37
233 (range 0.25 – 0.65) (Fig. 1D). Tumor purity was higher in ultrasonic aspirator tissue
234 samples compared to FFPE tissue for routine workup in 3 out of 4 (75%) cases.

235

236 **DNA methylation-based classification**

237 Tumors were classified based on DNA methylation profiles using a neural network
238 model which had been trained using the Heidelberg brain tumour reference cohort
239 with CNS tumor methylation datasets of 2,801 samples and predictions were made
240 with respect to the 91 methylation classes (MC) or methylation class family (MCF),
241 respectively, as defined in the 11b4 version (3). A single nanopore-specific cut-off
242 value was determined by recalibrating the raw values to identify valid predictions.
243 Receiver operating characteristic curve analysis of the maximum calibrated scores
244 was used to determine an optimal cut-off value > 0.2.

245 Classification results were identical to microarray in 16/18 (89%) of cases and
246 compatible with the integrative histopathological reference diagnosis in 16/18 (89%)
247 cases (Figure 2). Application of the optimal calibrated score threshold of >0.2
248 resulted in 14/18 cases passing the cut-off all of which were correctly classified,
249 corresponding to a specificity of 100% and a sensitivity of 78% on both MC and MCF
250 level (Figure 2).

251 At the MC level, in 2/18 (11%) cases, the score was below the optimal threshold but
252 classification was still correct (one YAP-fusion positive ependymoma, one
253 subependymal giant-cell astrocytoma (SEGA)). 2/18 (11%) cases had discordant
254 results with scores that were below the calibrated nanopore-specific threshold: In the
255 first case, pilocytic astrocytoma (PA) subtype was incorrect (classifying the case as
256 midline PA instead of posterior fossa PA) while correctly classifying the sample as PA
257 on MCF level. The other sample was an IDH-mutant astrocytoma classified as control
258 tissue. Here, additional Sanger sequencing revealed no IDH mutation in the
259 ultrasonic aspirator tissue sample, potentially indicating a sampling issue.

260 For comparison, the microarray-based analysis from matched FFPE tissue yielded a
261 diagnostic score in 16/18 (89%) cases. Of note, the two cases with nondiagnostic
262 score included one case of SEGA that also received a low score in
263 nanopore/ultrasonic aspirator tissue profiling.

264

265 **Copy number profiling**

266 Copy number profiles obtained from WGS closely resembled matched array-based
267 profiles in 16/18 (88.9 %) cases and enabled the detection of large chromosomal
268 alterations, whereas two nanopore-based CNVs (both pilocytic astrocytomas) were
269 insufficient for interpretation (Suppl. Figure 1). In contrast, low-level focal gains such
270 as tandem duplications resulting in *BRAF* fusion genes in the PA samples were
271 visually identified in 1/9 (11.1 %) cases from nanopore CNV profiles compared with
272 detection in 8/9 (88.8 %) in matched CNV profiles from methylation microarrays
273 (Suppl. Figure 1).

274

275 **Discussion**

276

277 Molecular testing is an essential component of state-of-the-art integrated
278 neuropathological diagnostics for most pediatric brain tumor types. Due to the
279 increasing number of pathological examinations required (such as DNA and RNA
280 gene panel sequencing or methylation microarray), tissue is valuable. This proof-of-
281 principle study reports, to our knowledge, the first application of ultrasonic aspirator-
282 derived tumor tissue for molecular classification of pediatric CNS tumors using low-
283 pass nanopore whole genome sequencing. We show that ultrasonic aspirator-derived
284 tumor fragments are a representative source of tumor DNA with tumor cell content
285 sufficient to DNA methylation-based classification and yielding identical classification
286 results.

287

288 **Tissue characteristics**

289 Although the use of ultrasonically minced tumor tissue for histopathological analysis
290 of brain tumor tissue has been demonstrated in some studies, the suitability is still
291 matter of debate (23-26). In particular, the grading of glial tumors has been reported
292 difficult as histomorphology was only partly recapitulated.

293 Using read length distribution of mapped nanopore reads as a proxy of DNA
294 fragment length, we find no significant difference in DNA extracted from fresh
295 ultrasonic aspirator tissue aspirates compared to routinely prepared fresh-frozen
296 tissue. Our analysis thus confirms that high molecular weight genomic DNA suitable
297 for nanopore sequencing can be extracted when ultrasonic aspirator-derived tissue is

298 used. Additionally, similar aligned base yields indicate comparable sequencing
299 performance. Tumor purity estimations for microarray and nanopore indicate a
300 tendency towards higher tumor purity in ultrasonic aspirator tissue samples.
301 However, the estimation depends on the existence of numerical chromosomal
302 alterations. As expected, the majority of cases within a pediatric cohort are pilocytic
303 astrocytomas which lack relevant aneuploidy. Therefore, tumor purity could only be
304 determined in 4 cases.

305 One of the major advantages of using ultrasonic aspirator tissue samples is that
306 multiple areas of the excised tumor are sampled (23). This is particularly important
307 because analyses based on single biopsies may have potential consequences for
308 treatment decisions in spatially and temporally heterogeneous pediatric tumors (27,
309 28). In contrast, DNA extraction for methylome profiling is usually done after
310 microdissection of a representative area of the tumor sample with an anticipated
311 tumor cell content of $\geq 70\%$ and therefore reflects only a subset of the entire tumor
312 (3).

313

314 **Comparison to microarray-based classification**

315 It was recently demonstrated, that the application of nanopore technology can be
316 used with comparable reliability for processing of fresh frozen tissue compared to
317 microarray-based analysis of FFPE material (9). Our analysis confirms its suitability
318 when using ultrasonic aspirator-derived tissue. Similar to the observed sensitivity of
319 88% in a well-defined validation cohort for microarray-based classification (3), our
320 approach reaches an overall accuracy of 89% and a sensitivity of 78% for the > 0.2
321 cut-off while retaining 100% specificity. In contrast, in a real-world cohort enriched for
322 challenging cases a sensitivity as low as 56% was reported for EPIC-based
323 microarray analysis (29).

324 Especially low-tumor cell content, like in the infiltration zone of diffuse glioma, can be
325 challenging for the performance of DNA methylation-based classification (30) and
326 was likely the cause for the discordantly classified cases (before application of
327 diagnostic cut-offs) in this cohort. Therefore, low tumor cell content poses a
328 challenge to methylation-based classification in general, independent of the
329 processed tissue type or technology platform used for methylome profiling.

330 Copy number profiles can be derived both from nanopore low-pass WGS and
331 methylation microarray datasets. While the resolution of microarray-based CNV plots

332 is fixed due to the probe set of the chip, resolution of low-pass WGS-based CNV
333 plots correlates with read yield. In our cohort, the quality of nanopore CNV plots was
334 frequently inferior to the matched microarray-based ones. However, next generation
335 flow cells and chemistries for nanopore sequencing devices offer better yields and
336 are likely to resolve these issues.

337

338 *Conclusion*

339 DNA methylation-based classification of pediatric CNS tumors from ultrasonic
340 aspirator-fragmented tissue is feasible using nanopore sequencing. A neural network
341 classifier with nanopore-specific diagnostic score thresholds assures high specificity
342 while achieving acceptable sensitivity. Generation of CN profiles is possible and
343 allows for detection of chromosomal changes, but was currently inferior in detection
344 of focal changes (e.g. *BRAF* tandem duplication) compared to microarray
345 approaches. This approach allows maximum exploitation of available tissue for
346 diagnostics. Since advanced molecular techniques have limited benefit for patients in
347 resource-challenged centers, our time- and cost-efficient approach may be of
348 particular interest.

349

350 **Acknowledgments**

351 We thank Aydah Sabah for expert technical assistance. Computation has been
352 performed on the HPC for Research cluster of the Berlin Institute of Health. P.E. has
353 been a participant in the BIH-Charité Clinical Scientist Program funded by the Charité
354 – Universitätsmedizin Berlin and BIH.

355 Figures were created in part using Servier Medical Art provided by Servier and
356 licensed under a Creative Commons Attribution 3.0 unported license. In addition,
357 images illustrating nanopore sequencing were reproduced with permission from
358 Oxford Nanopore Technologies Plc, United Kingdom.

359

360 **Conflicts of interest**

361 PHD is ICI of the Sprinkle study and advisory board member for Alexion. DC declares
362 a patent for a method to classify tumors according to DNA methylation signature. All
363 other authors declare no conflicts of interest.

364

365 **References**

366

- 367 1. Zebian B, Vergani F, Lavrador JP, Mukherjee S, Kitchen WJ, Stagno V, et al.
368 Recent technological advances in pediatric brain tumor surgery. *CNS Oncol.*
369 2017;6(1):71-82.
- 370 2. Sturm D, Capper D, Andreiuolo F, Gessi M, Kolsche C, Reinhardt A, et al.
371 Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology.
372 *Nat Med.* 2023;29(4):917-26.
- 373 3. Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA
374 methylation-based classification of central nervous system tumours. *Nature.*
375 2018;555(7697):469-74.
- 376 4. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al.
377 The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
378 *Neuro Oncol.* 2021;23(8):1231-51.
- 379 5. Truong LN, Patil S, Martin SS, LeBlanc JF, Nanda A, Nordberg ML, et al.
380 Rapid detection of high-level oncogene amplifications in ultrasonic surgical
381 aspirations of brain tumors. *Diagn Pathol.* 2012;7:66.
- 382 6. Alenda C, Rojas E, Valor LM. FFPE samples from cavitation ultrasonic
383 surgical aspirates are suitable for RNA profiling of gliomas. *PLoS One.*
384 2021;16(7):e0255168.
- 385 7. Merchant TE, Pollack IF, Loeffler JS. Brain tumors across the age spectrum:
386 biology, therapy, and late effects. *Semin Radiat Oncol.* 2010;20(1):58-66.
- 387 8. Gojo J, Kjaersgaard M, Zezschwitz BV, Capper D, Tietze A, Kool M, et al.
388 Rare embryonal and sarcomatous central nervous system tumours: State-of-the art
389 and future directions. *Eur J Med Genet.* 2023;66(1):104660.
- 390 9. Kuschel LP, Hench J, Frank S, Hench IB, Girard E, Blanluet M, et al. Robust
391 methylation-based classification of brain tumours using nanopore sequencing.
392 *Neuropathol Appl Neurobiol.* 2022:e12856.
- 393 10. Djirackor L, Halldorsson S, Niehusmann P, Leske H, Capper D, Kuschel LP, et
394 al. Intraoperative DNA methylation classification of brain tumors impacts
395 neurosurgical strategy. *Neurooncol Adv.* 2021;3(1):vdab149.
- 396 11. Patel A, Dogan H, Payne A, Krause E, Sievers P, Schoebe N, et al. Rapid-
397 CNS(2): rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a
398 proof-of-concept study. *Acta Neuropathol.* 2022;143(5):609-12.
- 399 12. Branton D, Deamer DW, Marziali A, Bayley H, Benner SA, Butler T, et al. The
400 potential and challenges of nanopore sequencing. *Nat Biotechnol.* 2008;26(10):1146-
401 53.
- 402 13. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
403 electronic data capture (REDCap)--a metadata-driven methodology and workflow
404 process for providing translational research informatics support. *J Biomed Inform.*
405 2009;42(2):377-81.
- 406 14. Li H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics.*
407 2018;34(18):3094-100.
- 408 15. Simpson JT, Workman RE, Zuzarte PC, David M, Dursi LJ, Timp W. Detecting
409 DNA cytosine methylation using nanopore sequencing. *Nat Methods.*
410 2017;14(4):407-10.
- 411 16. Paszke A, Gross S, Massa F, Lerer A, Bradbury J, Chanan G, et al. Pytorch:
412 An imperative style, high-performance deep learning library. *Advances in neural*
413 *information processing systems.* 2019;32.
- 414 17. van der Maaten L; Hinton G. Visualizing data using t-sne. *Journal of Machine*
415 *Learning Research,* 9(Nov):2579–2605, 2008.

- 416 18. Euskirchen P, Bielle F, Labreche K, Kloosterman WP, Rosenberg S, Daniau
417 M, et al. Same-day genomic and epigenomic diagnosis of brain tumors using real-
418 time nanopore sequencing. *Acta Neuropathol.* 2017;134(5):691-703.
- 419 19. Scheinin I, Sie D, Bengtsson H, van de Wiel MA, Olshen AB, van Thuijl HF, et
420 al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow
421 whole-genome sequencing with identification and exclusion of problematic regions in
422 the genome assembly. *Genome Res.* 2014;24(12):2022-32.
- 423 20. Poell JB, Mendeville M, Sie D, Brink A, Brakenhoff RH, Ylstra B. ACE:
424 absolute copy number estimation from low-coverage whole-genome sequencing
425 data. *Bioinformatics.* 2019;35(16):2847-9.
- 426 21. Koster J, Rahmann S. Snakemake--a scalable bioinformatics workflow engine.
427 *Bioinformatics.* 2012;28(19):2520-2.
- 428 22. Moudgil-Joshi J, Kaliaperumal C. Letter regarding Louis et al: The 2021 WHO
429 Classification of Tumors of the Central Nervous System: A summary. *Neuro Oncol.*
430 2021;23(12):2120-1.
- 431 23. Rao S, Vazhayil V, Nandeesh BN, Beniwal M, Rao K, Yasha TC, et al.
432 Diagnostic Utility of CUSA Specimen in Histopathological Evaluation of Tumors of
433 Central Nervous System. *Neurol India.* 2020;68(6):1385-8.
- 434 24. Finley JL, Silverman JF, Dickens MA. Immunocytochemical evaluation of
435 central nervous system tumors obtained by the Cavitron ultrasonic surgical aspirator.
436 *Diagn Cytopathol.* 1990;6(5):308-12.
- 437 25. Silverman JF, Jones FD, Unverferth M, Berns L. Cytopathology of neoplasms
438 of the central nervous system in specimens obtained by the Cavitron Ultrasonic
439 Surgical Aspirator. *Acta Cytol.* 1989;33(5):576-82.
- 440 26. Richmond IL, Hawksley CA. Evaluation of the histopathology of brain tumor
441 tissue obtained by ultrasonic aspiration. *Neurosurgery.* 1983;13(4):415-9.
- 442 27. Schmelz K, Toedling J, Huska M, Cwikla MC, Krutzfeldt LM, Proba J, et al.
443 Spatial and temporal intratumour heterogeneity has potential consequences for
444 single biopsy-based neuroblastoma treatment decisions. *Nat Commun.*
445 2021;12(1):6804.
- 446 28. Lazow MA, Hoffman L, Schafer A, Osorio DS, Boue DR, Rush S, et al.
447 Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas. *Acta*
448 *Neuropathol Commun.* 2020;8(1):182.
- 449 29. Jaunmuktane Z, Capper D, Jones DTW, Schrimpf D, Sill M, Dutt M, et al.
450 Methylation array profiling of adult brain tumours: diagnostic outcomes in a large,
451 single centre. *Acta Neuropathol Commun.* 2019;7(1):24.
- 452 30. Capper D, Stichel D, Sahm F, Jones DTW, Schrimpf D, Sill M, et al. Practical
453 implementation of DNA methylation and copy-number-based CNS tumor diagnostics:
454 the Heidelberg experience. *Acta Neuropathol.* 2018;136(2):181-210.
455

456

457 **Figure legends**

458

459 **Figure 1: (A)** Overview of the study design including workflow using ultrasonic
460 aspirator tissue specimens for nanopore sequencing for DNA methylation-based
461 classification using a neural network classifier and copy number variation analysis,
462 comparison to microarray-based routine neuropathological profiling and assessment
463 of tumor purity by absolute copy number estimation using ACE. Suitability of
464 ultrasonic aspirator-derived tumor tissue (UA) for nanopore sequencing (T-Test and
465 Mann-Whitney U with $P > .05$): **(B,C)** Comparison of **(B)** mean read length and **(C)**
466 read yield obtained from standard nanopore protocol using fresh-frozen (FrFr) tumor
467 tissue vs. ultrasonic aspirator-derived sample material indicates similar sequencing
468 performance. **(D)** In silico tumor purity estimation between nanopore ultrasonic
469 aspirator tissue samples and microarray FFPE tissue. **(E,F)** Representative
470 illustration of matched copy number variation profiles obtained from **(E)** ultrasonic
471 aspirator tissue samples and nanopore sequencing and **(F)** FFPE tumor tissue
472 subjected to EPIC microarray (850K). Red marker indicates a low-level gain of the
473 *BRAF* locus suggestive of a *BRAF* gene fusion.

474

475 **Figure 2:** Nanopore classification methylation class call of ultrasonic aspirator-
476 derived tumor material and the corresponding 2016 WHO CNS reference diagnosis
477 results showing a specificity of 100% and sensitivity of 77.7 % for cases above the
478 calibrated threshold of > 0.2 .

479

480 **Suppl. Figure 1:** Comparison of copy number variation profiles obtained from **(A)**
481 ultrasonic aspirator tissue samples and nanopore sequencing and **(B)** FFPE tumor
482 tissue subjected to EPIC microarray (850K).

483







484 **Table 1:** Overview of the patient cohort.


485

486

487


488






(A)

Ultrasonic aspirator I DX-BLN-025




(B)

Microarray I DX-BLN-025




(A)

Ultrasonic aspirator I DX-BLN-027




(B)

Microarray I DX-BLN-027




(A)

Ultrasonic aspirator I DX-BLN-028




(B)

Microarray I DX-BLN-028




(A)

Ultrasonic aspirator I DX-BLN-029




(B)

Microarray I DX-BLN-029




(A)

Ultrasonic aspirator I DX-BLN-037




(B)

Microarray I DX-BLN-037




(A)

Ultrasonic aspirator I DX-BLN-042




(B)

Microarray I DX-BLN-042




(A)

Ultrasonic aspirator I DX-BLN-043




(B)

Microarray I DX-BLN-043




(A)

Ultrasonic aspirator I DX-BLN-044a




(B)

Microarray I DX-BLN-044a




(A)

Ultrasonic aspirator I DX-BLN-047




(B)

Microarray I DX-BLN-047




(A)

Ultrasonic aspirator I DX-BLN-048




(B)

Microarray I DX-BLN-048




(A)

Ultrasonic aspirator I DX-BLN-049a




(B)

Microarray I DX-BLN-049a




(A)

Ultrasonic aspirator I DX-BLN-050




(B)

Microarray I DX-BLN-050




(A)

Ultrasonic aspirator I DX-BLN-054




(B)

Microarray I DX-BLN-054




(A)

Ultrasonic aspirator I DX-BLN-057




(B)

Microarray I DX-BLN-057




(A)

Ultrasonic aspirator I DX-BLN-064




(B)

Microarray I DX-BLN-064




(A)

Ultrasonic aspirator I DX-BLN-065




(B)

Microarray I DX-BLN-065




(A)

Ultrasonic aspirator I DX-BLN-071




(B)

Microarray I DX-BLN-071




(A)

Ultrasonic aspirator I DX-BLN-072




(B)

Microarray I DX-BLN-072




(A)

Ultrasonic aspirator I DX-BLN-074




(B)

Microarray I DX-BLN-074




(A)

Ultrasonic aspirator I DX-BLN-075



(B)

Microarray I DX-BLN-075



Patient ID	Sex	CNS WHO 2016	Microarray methylation class	Probability score	Nanopore methylation class family	tSNE methylation class family concordance	Nanopore methylation class	tSNE methylation class concordance
DX-BLN-025	F	CNS neuroblastoma	CNS neuroblastoma with FOXR2 activation	0,682	CNS neuroblastoma with FOXR2 activation	+	CNS neuroblastoma with FOXR2 activation	+
DX-BLN-027	F	Schwannoma	schwannoma	0,854	schwannoma	+	schwannoma	+
DX-BLN-028	F	Pilocytic astrocytoma	low grade glioma, subclass posterior fossa pilocytic astrocytoma	0,583	pilocytic astrocytoma	+	low grade glioma, subclass posterior fossa pilocytic astrocytoma	+
DX-BLN-029	F	Ependymoma	ependymoma, YAP fusion	0,101	glioblastoma, IDH wildtype	+	ependymoma, YAP fusion	+
DX-BLN-037	F	Pilocytic astrocytoma	low grade glioma, subclass posterior fossa pilocytic astrocytoma	0,539	pilocytic astrocytoma	+	low grade glioma, subclass posterior fossa pilocytic astrocytoma	+
DX-BLN-042	F	Pilocytic astrocytoma	low grade glioma, subclass posterior fossa pilocytic astrocytoma	0,557	pilocytic astrocytoma	+	low grade glioma, subclass posterior fossa pilocytic astrocytoma	+
DX-BLN-043	M	Ependymoma, RELA fusion-positive	ependymoma, RELA fusion	0,428	ependymoma, RELA fusion	+	ependymoma, RELA fusion	+
DX-BLN-047	F	Pilocytic astrocytoma	low grade glioma, subclass posterior fossa pilocytic astrocytoma	0,5	pilocytic astrocytoma	+	low grade glioma, subclass posterior fossa pilocytic astrocytoma	+
DX-	M	Anaplastic	ependymoma,	0,754	ependymoma,	+	ependymoma,	+

BLN-048		Ependymoma	posterior fossa group A		posterior fossa group A		posterior fossa group A	
DX-BLN-049	F	Pilocytic astrocytoma	low grade glioma, subclass posterior fossa pilocytic astrocytoma	0,12	pilocytic astrocytoma	-	low grade glioma, subclass midline pilocytic astrocytoma	-
DX-BLN-050	F	Atypical central neurocytoma	central neurocytoma	0,721	central neurocytoma	+	central neurocytoma	+
DX-BLN-054	F	Diffuse astrocytoma, IDH-mutant	IDH glioma, subclass astrocytoma	0,166	pilocytic astrocytoma	-	control tissue, hemispheric cortex	-
DX-BLN-064	F	Subependymal giant cell astrocytoma	#NV	0,15	low grade glioma, subependymal giant cell astrocytoma	-	low grade glioma, subependymal giant cell astrocytoma	-
DX-BLN-065	M	Pilocytic astrocytoma	low grade glioma, subclass posterior fossa pilocytic astrocytoma	0,472	pilocytic astrocytoma	+	low grade glioma, subclass posterior fossa pilocytic astrocytoma	+
DX-BLN-071	F	Pilocytic astrocytoma	#NV	0,485	pilocytic astrocytoma	+	low grade glioma, subclass midline pilocytic astrocytoma	+
DX-BLN-073	M	Craniopharyngioma	craniopharyngioma, adamantinomatous	0,555	craniopharyngioma, adamantinomatous	+	craniopharyngioma, adamantinomatous	+
DX-BLN-074	M	Pilocytic astrocytoma	low grade glioma, subclass posterior fossa pilocytic astrocytoma	0,691	pilocytic astrocytoma	+	low grade glioma, subclass posterior fossa pilocytic astrocytoma	+
DX-BLN-	M	Pilocytic astrocytoma	low grade glioma, subclass posterior	0,405	pilocytic astrocytoma	+	low grade glioma, subclass posterior	+

075			fossa pilocytic astrocytoma				fossa pilocytic astrocytoma	
-----	--	--	--------------------------------	--	--	--	--------------------------------	--